Enzyme inhibitors of PAI-1

Details Enzyme inhibitors of PAI-1 Enzyme inhibitors of PAI-1

2006-10-10

2011-11-29

Audet, Maury (Department: 1654)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C514S001100, C530S380000, C435S023000

Reexamination Certificate

active

08066991

ABSTRACT:
The invention provides a method for the treatment of a subject suffering from a cardiovascular disease using a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. The invention also provides a method of decreasing the risk of the occurrence of a cardiovascular disease in a subject who presents at least one risk factor that is associated with a cardiovascular disease, by administering to the subject a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. Additionally, the invention provides a method of inhibiting PAI-1 activity in a subject in need thereof, where the subject is administered an enzyme selected from a protease or peptidase.

REFERENCES:
patent: 3860702 (1975-01-01), Buell
patent: 5328909 (1994-07-01), Ando et al.
patent: 5731328 (1998-03-01), Berg et al.
patent: 2002/0115843 (2002-08-01), Oi et al.
patent: 2003/0199462 (2003-10-01), Nunez et al.
patent: 2005/0158295 (2005-07-01), Swiercz et al.
patent: 1 627 885 (2006-02-01), None
patent: 2 233 038 (1975-01-01), None
patent: WO 95/00169 (1995-01-01), None
patent: WO 2004/ 096843 (2004-11-01), None
Andreason et al. “Solvent effects on activity and conformation of plasminogen activator inhibitor-1.” Thrombosis and Haemostasis (1999), 81(3), 407-414.
Urano et al., “The Profibrinolytic Enzyme Subtilisin NAT Purified fromBacillus subtilisCleaves and Inactivates Plasminogen Activator Inhibitor,”The Journ. Of Biol. Chem., vol. 276, No. 27, 2001, pp. 24690-24696.
Luisetti et al., “Some Properties of the Alkaline Proteinase fromAspergillus melleus,” Int. J. Tiss. Reac. XIII(4), 1991, pp. 187-192.
Fossati, “Antiinflammatory Effects of Seaprose-S on Various Inflammation Models,” Drugs Exptl. Clin. Res. XXV(6), 1999, pp. 263-270.
Braga et al., “Effects of Seaprose on the Rheology of Bronchial Mucus in Pateints with chronic Bronchitis. A Double-Blind Study vs. Placebo,” Int. J. clin. Pharm. Res. XIII(3), 1993, pp. 179-185.
Braga et al., “The Influence of Seaprose on Erythromycin Penetration into Bronchial Mucus in Bronchopulmonary Infections,” Drugs Exptl. Clin. Res. XVIII(3), 1992, pp. 105-111.
Moretti et al., “Effects of Seaprose on Sputum Biochemical Components in Chronic Bronchitic Patients: A Double-Blind Study vs. Placebo,” Int. J. Clin. Pharm. Res. XIII(5), 1993, pp. 275-280.
Moriya et al., “Intestinal Absorption of Serrapeptase (TSP) in Rats,” Biotechnol. Appl. Biochem. 20, 1994, pp. 101-108.
Castell et al., “Intestinal Absorption of Undegraded Proteins in Men: Presence of Bromelain in Plasma After Oral Intake,” 1997, pp. 139-146.
Wu et al., “Inhibition of PAI-1: A New Anti-Thrombotic Approach,” 2002, pp. 27-42.
Duffy, “Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: from Pilot to level I Evidence Studies,” Clinical Chemistry 48:8, 2002, pp. 1194-1197.
Robbie et al., “Inhibitors of Fibrinolysis Are Elevated in Atherosclerotic Plaque,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, No. 4, 1996, pp. 539-545.
Escandon et al., “Amelioration of the inhibition of Fibrinolysis in Elderly, Obese Subjects by Moderate Energy Intake Restriction,” Am. J. Clin. Nutr. 1996, pp. 7-11.
Vaughan et al., “Plasminogen Activator Inhibitor-1: A Common Denominator in Cardiovascular Disease,” Journal of Investigative Medicine, vol. 46, No. 8, 1998, pp. 370-376.
Sobel et al., “Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens from Type 2 Diabetic Compared with Nondiabetic Patients,” 1998, pp. 2213-2221.
Pandolfi et al., Plasminogen Activator Inhibitor Type 1 is Increased in the Arterial wall of Type II Diabetic Subjects, Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, pp. 1378-1382.
Mertens et al., “Visceral Fat as a Determinant of Fibrinolysis and Hemostasis,” Seminars in Vascular Medicine, vol. 5, No. 1, 2005, pp. 48-55.
Hamsten et al., “Plasminogen Activator Inhibitor in Plasma: Risk Factor for Recurrent Myocardial Infarction,” The Lancet, 1987, pp. 3-9.
Lijnen, Pleitropic Functions of Plasminogen Activator Inhibotor-1, Journ. Of Thrombosis and Haemostasis, 3: 2004, pp. 35-45.
Yamamoto, “Aging and Plasminogen Activator Inhibitor-1 (PAI-1) regulation: implication in the Pathogenesis of Thrombotic Disorders in the Elderly,” Cardiovascular Research 66, 2005, pp. 276-285.
Taeye, et al., “Plasminogen Activator Inhibitor-1: A Common Denominator in Obesity, Diabetes and Cardiovascular Disease,” 2005, pp. 149-154.
Festa et al., Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes, 2002, pp. 1131-1137.
Ye et al., Synthesis and Biological Evaluation of Piperazine-Based Derivatives as Inhibitors of Plasminogen Activator lnibitor-1 (PAI-1), 2004, pp. 761-765.
Friederich et al., “Novel Low-Molecular-Weight Inhibitor of PAI-1 (XR5118) Promotes Endogenous Fibrinolysis and Reduces Postthrombolysis Thrombus Growth in Rabbits,” 1997, pp. 916-921.
Berry et al., “Antithrombotic Activity of a Monoclonal Antibody Inducing the Substrate Form of Plasminogen Activator Inhibitor Type 1 in Rat Models of Venous and Arterial Thrombosis,” 1998, pp. 29-34.
Giezen et al., “The Fab-Fragment of a PAI-1 Inhibiting Antibody Reduces Thrombus Size and Restores Blood Flow in a Rat Model of Arterial Thrombosis,” 1997, pp. 964-969.
Fay, et al., “Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene,” 1997, pp. 204-208.
Crandall et al., “Characterization and Comparative Evaluation of a Structurally Unique PAI-1 Inhibitor Exhibiting Oral In-Vivo Efficacy,” 2004, pp. 1422-1428.
Biemond et al., Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis, 1995, pp. 1175-1181.
Carmeliet et al., “Plasminogen Activator Inhibitor-1 Gene-Deficient Mice: II. Effects on Hemostasis, Thrombosis, and Thrombolysis,” The Journ. Of Clin. Invest., vol. 92(6), 1993, pp. 1-12.
Elokdah et al., Tiplaxtinin, A Novel, Orally Efficacious Inhibitor of Plasminogen Activator Inhibitor-1: Design, Synthesis, and Preclinical Characterization, 2004, pp. 3491-3494.
Levi et al., Inhibition of Plasminogen Activator Inhibotor-1 Activity Results in Promotion of Endogenous Thrombolysis and inhibition of Thrombus Extension in Models of Experimental Thrombosis, 1992, pp. 305-312.
Liang et al., Characterization of a Small Molecule PAI-1 Inhibitor, ZK4044, 2005, pp. 341-350.
Sumi, H., et al., “Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase,” Copyright 1998 Elsevier Science B.V. Amsterdam, 1990 EMB-1990367850, Acta Haematologica, pp. 139-143, vol. 84, No. 3, abstract, [XP-002441112].
“Novel digestive organ absorptive polypeptide, useful for detecting toxicity of test substance in living organism, treating glucose tolerance disorder, type II diabetes, for manufacturing ice cream, soft drink, fruit drink,” Derwent Publications Ltd., London, 2004-804720, 2004, abstract [XP-002441290].
Metzig, C., et al., “Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo,” Biosciences Information Service, 1999, pp. 7-12, vol. 13, No. 1, abstract [XP-00244118].
Gutfreund A.E., et al., “Effect of oral bromelain on blood pressure and heart rate of hypertensive patients,” Copyright 1998 Elsevier Science B.V., Amsterdam, 1978, pp. 143-146, vol. 37, No. 5, abstract [XP-002441120].
Hofbauer, R., “Modern aspects of bromelain: A brief review,” Copyright 2003 Elsevier Sceince B.V., Amsterdam, 2002, pp. 50-55, vol. 3, No.

Affiliated with

Also associated with

Rating

Enzyme inhibitors of PAI-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enzyme inhibitors of PAI-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme inhibitors of PAI-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4278172